Cargando…

Genetic Addiction Risk and Psychological Profiling Analyses for “Preaddiction” Severity Index

Since 1990, when our laboratory published the association of the DRD2 Taq A1 allele and severe alcoholism in JAMA, there has been an explosion of genetic candidate association studies, including genome-wide association studies (GWAS). To develop an accurate test to help identify those at risk for at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blum, Kenneth, Han, David, Bowirrat, Abdalla, Downs, Bernard William, Bagchi, Debasis, Thanos, Panayotis K., Baron, David, Braverman, Eric R., Dennen, Catherine A., Gupta, Ashim, Elman, Igor, Badgaiyan, Rajendra D., Llanos-Gomez, Luis, Khalsa, Jag, Barh, Debmalya, McLaughlin, Thomas, Gold, Mark S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696872/ https://www.ncbi.nlm.nih.gov/pubmed/36579510 http://dx.doi.org/10.3390/jpm12111772

Ejemplares similares

“Preaddiction” construct and reward deficiency syndrome: genetic link via dopaminergic dysregulation
por: Blum, Kenneth, et al.
Publicado: (2022)

Should Reward Deficiency Syndrome (RDS) Be Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic Induced Dysregulation of Brain Reward Circuitry?
por: Blum, Kenneth, et al.
Publicado: (2022)

Hypothesizing That Pediatric Autoimmune Neuropsychiatric Associated Streptococcal (PANDAS) Causes Rapid Onset of Reward Deficiency Syndrome (RDS) Behaviors and May Require Induction of “Dopamine Homeostasis”
por: Blum, Kenneth, et al.
Publicado: (2022)

Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids
por: Ceccanti, Mauro, et al.
Publicado: (2022)

Neurogenetic and Epigenetic Aspects of Cannabinoids
por: Dennen, Catherine A., et al.
Publicado: (2022)

Invited Expert Opinion- Bioinformatic and Limitation Directives to Help Adopt Genetic Addiction Risk Screening and Identify Preaddictive Reward Dysregulation: Required Analytic Evidence to Induce Dopamine Homeostatsis
por: Blum, Kenneth, et al.
Publicado: (2023)

Theorizing the Role of Dopaminergic Polymorphic Risk Alleles with Intermittent Explosive Disorder (IED), Violent/Aggressive Behavior and Addiction: Justification of Genetic Addiction Risk Severity (GARS) Testing
por: Modestino, Edward Justin, et al.
Publicado: (2022)

Genetic Addiction Risk Severity Assessment Identifies Polymorphic Reward Genes as Antecedents to Reward Deficiency Syndrome (RDS) Hypodopaminergia’s Effect on Addictive and Non-Addictive Behaviors in a Nuclear Family
por: Dennen, Catherine A., et al.
Publicado: (2022)

Positive Clinical Outcomes for Severe Reported Pain Using Robust Non-Addictive Home Electrotherapy—A Case-Series
por: Bajaj, Anish, et al.
Publicado: (2023)

Beyond Mor: Can Induction of Dopamine Homeostasis Along with Electrotherapy Attenuate the Opioid Crisis?
por: Blum, Kenneth, et al.
Publicado: (2023)

Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,566 Case–Control Subjects
por: Blum, Kenneth, et al.
Publicado: (2022)

Neurogenetics and Epigenetics of Loneliness
por: Bowirrat, Abdalla, et al.
Publicado: (2023)

How to Combat the Global Opioid Crisis
por: Dennen A., Catherine, et al.
Publicado: (2023)

Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction?
por: Blum, Kenneth, et al.
Publicado: (2021)

A Novel Precision Approach to Overcome the “Addiction Pandemic” by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration
por: Blum, Kenneth, et al.
Publicado: (2021)

Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All Addictions
por: Blum, Kenneth, et al.
Publicado: (2021)

Precision Behavioral Management (PBM) and Cognitive Control as a Potential Therapeutic and Prophylactic Modality for Reward Deficiency Syndrome (RDS): Is There Enough Evidence?
por: Madigan, Margaret A., et al.
Publicado: (2022)

DNA Directed Pro-Dopamine Regulation Coupling Subluxation Repair, H-Wave(®) and Other Neurobiologically Based Modalities to Address Complexities of Chronic Pain in a Female Diagnosed with Reward Deficiency Syndrome (RDS): Emergence of Induction of “Dopamine Homeostasis” in the Face of the Opioid Crisis
por: Bajaj, Anish, et al.
Publicado: (2022)

Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It “Blowin’ in the Wind”?
por: Blum, Kenneth, et al.
Publicado: (2022)

Researching Mitigation of Alcohol Binge Drinking in Polydrug Abuse: KCNK13 and RASGRF2 Gene(s) Risk Polymorphisms Coupled with Genetic Addiction Risk Severity (GARS) Guiding Precision Pro-Dopamine Regulation
por: Blum, Kenneth, et al.
Publicado: (2022)

A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing “Precision Behavioral Management”
por: Blum, Kenneth, et al.
Publicado: (2021)

Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive Behaviors
por: Gupta, Ashim, et al.
Publicado: (2022)

Metheamphetamine for Children: Are We Over or Under Dosing?
por: Blum, Kenneth, et al.
Publicado: (2023)

Offering a putative neurobiological “dopamine homeostatic” solution to overcome the perils of the reward deficiency syndrome pandemic: emergence of “precision behavioral management”
por: Blum, Kenneth, et al.
Publicado: (2022)

KB220Z™ a Pro-Dopamine Regulator Associated with the Protracted, Alleviation of Terrifying Lucid Dreams. Can We Infer Neuroplasticity-induced Changes in the Reward Circuit?
por: McLaughlin, Thomas, et al.
Publicado: (2016)

Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors
por: Blum, Kenneth, et al.
Publicado: (2018)

Evidence for the DRD2 Gene as a Determinant of Reward Deficiency Syndrome (RDS)
por: Blum, Kenneth, et al.
Publicado: (2023)

Proposing a “Brain Health Checkup (BHC)” as a Global Potential “Standard of Care” to Overcome Reward Dysregulation in Primary Care Medicine: Coupling Genetic Risk Testing and Induction of “Dopamine Homeostasis”
por: Braverman, Eric R., et al.
Publicado: (2022)

Bariatric surgery: Potential post-operative heightened sensitivity to substances or behaviors
por: Thanos, Panayotis K., et al.
Publicado: (2021)

Induction of homeostatic biological parameters in reward deficiency as a function of an iron-free multi-nutrient complex: Promoting hemoglobinization, aerobic metabolism, viral immuno-competence, and neuroinflammatory regulation
por: Blum, Kenneth, et al.
Publicado: (2020)

Coupling Genetic Addiction Risk Score (GARS) with Electrotherapy: Fighting Iatrogenic Opioid Dependence
por: Blum, Kenneth, et al.
Publicado: (2013)

Hypothesizing Las Vegas and Sutherland Springs Mass Shooters Suffer from Reward Deficiency Syndrome: “Born Bad”
por: McLaughlin, Thomas, et al.
Publicado: (2017)

Exercise Modulates Brain Glucose Utilization Response to Acute Cocaine
por: Hanna, Colin, et al.
Publicado: (2022)

“TO BE OR NOT TO BE” GWAS Ends the Controversy about the DRD2 Gene as a Determinant of Reward Deficiency Syndrome (RDS)
por: Blum, Kenneth, et al.
Publicado: (2023)

High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial
por: Moran, Mark, et al.
Publicado: (2021)

Cannabis-Induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans: Embracing Putative Induction of Dopamine Homeostasis
por: Blum, Kenneth, et al.
Publicado: (2021)

Addiction by Any Other Name is Still Addiction: Embracing Molecular Neurogenetic/Epigenetic Basis of Reward Deficiency
por: Edwards, Drew, et al.
Publicado: (2020)

Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated)
por: Kenneth, Blum, et al.
Publicado: (2018)

Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD)
por: Blum, K, et al.
Publicado: (2019)

Improvement of long-term memory access with a pro-dopamine regulator in an elderly male: Are we targeting dopamine tone?
por: McLaughlin, Thomas, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bk17tt63rjm9v2p6go8eo3elbp